Table 4.
The correlation between pathological parameters and GSTM4 expression.
| Characteristic | Low expression of GSTM4 | High expression of GSTM4 | p |
|---|---|---|---|
| n | 189 | 190 | |
| FIGO stage, n (%) | 0.092 | ||
| Stage I | 1 (0.3%) | 0 (0%) | |
| Stage II | 12 (3.2%) | 11 (2.9%) | |
| Stage III | 155 (41.2%) | 140 (37.2%) | |
| Stage IV | 21 (5.6%) | 36 (9.6%) | |
| Primary therapy outcome, n (%) | 0.998 | ||
| PD | 14 (4.5%) | 13 (4.2%) | |
| SD | 11 (3.6%) | 11 (3.6%) | |
| PR | 22 (7.1%) | 21 (6.8%) | |
| CR | 112 (36.4%) | 104 (33.8%) | |
| Race, n (%) | 0.020 | ||
| Asian | 7 (1.9%) | 5 (1.4%) | |
| Black or African American | 6 (1.6%) | 19 (5.2%) | |
| White | 172 (47.1%) | 156 (42.7%) | |
| Age, n (%) | 0.714 | ||
| <=60 | 106 (28%) | 102 (26.9%) | |
| >60 | 83 (21.9%) | 88 (23.2%) | |
| Histologic grade, n (%) | 0.056 | ||
| G1 | 0 (0%) | 1 (0.3%) | |
| G2 | 29 (7.9%) | 16 (4.3%) | |
| G3 | 157 (42.5%) | 165 (44.7%) | |
| G4 | 0 (0%) | 1 (0.3%) | |
| Anatomic neoplasm subdivision, n (%) | 0.750 | ||
| Unilateral | 53 (14.8%) | 49 (13.7%) | |
| Bilateral | 126 (35.3%) | 129 (36.1%) | |
| Venous invasion, n (%) | 0.046 | ||
| No | 16 (15.2%) | 25 (23.8%) | |
| Yes | 39 (37.1%) | 25 (23.8%) | |
| Lymphatic invasion, n (%) | 0.351 | ||
| No | 21 (14.1%) | 27 (18.1%) | |
| Yes | 54 (36.2%) | 47 (31.5%) | |
| Tumor residual, n (%) | 0.461 | ||
| NRD | 31 (9.3%) | 36 (10.7%) | |
| RD | 140 (41.8%) | 128 (38.2%) | |
| Tumor status, n (%) | 0.284 | ||
| Tumor free | 32 (9.5%) | 40 (11.9%) | |
| With tumor | 139 (41.2%) | 126 (37.4%) | |
| Age, meidan (IQR) | 58 (50, 68) | 59 (52, 68) | 0.345 |